Arunpreet Kahlon
Interventional Cardiology · Lone Tree, CONPI 1437582202
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Penumbra, Inc. at 44.2% of the total.
Across 420 payments — averaging $87.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$16K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- Medtronic$2K
- Abbott$1K
- Boston Scientific$1K
- Inari Medical, Inc.$1K
- plus $7K from 42 others
What the payments were for
- Speaking & faculty fees$17,80048%
- Travel & lodging$4,92813%
- Food & beverage$13,67737%
- Education$4691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$15,688
- LifeVest$7,000
- FLOWTRIEVER CATHETER, S$1,177
- CT THROMBECTOMY SYSTEM KIT$1,177
- RESOLUTE ONYX$719
- SAPIEN 3 Ultra RESILIA$509
- ONYX FRONTIER$461
- OPTIS$443
- Omnilink Elite vascular stent system$370
- Penumbra System$256
- GENERAL - STRUCTURAL HEART$247
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$212
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$186
- MitraClip$172
- TRAPLINER$170
- SYMPLICITY G3$160
- GENERAL - THERAPIES$156
- Perclose ProGlide suture mediated closure system$141
- Ensite Cardiac Mapping System$141
- Cleerly Ischemia$140
How this compares
$36,874 in reported general payments places this provider in the 80th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $222,708 |
| FarxigaDapagliflozin Propanediol | 76 | $80,825 |
| OzempicSemaglutide | 39 | $57,872 |
| JardianceEmpagliflozin | 33 | $48,570 |
| XareltoRivaroxaban | 34 | $37,020 |
| MounjaroTirzepatide | 30 | $33,781 |
| EntrestoSacubitril/Valsartan | 15 | $25,994 |
| Repatha SureclickEvolocumab | 31 | $25,346 |
| WegovySemaglutide | 16 | $22,896 |
| Ranolazine ErRanolazine | 37 | $4,413 |
| Prasugrel Hcl | 24 | $3,587 |
| Metoprolol Succinate | 211 | $2,880 |
| Rosuvastatin Calcium | 244 | $2,583 |
| Ezetimibe | 56 | $2,162 |
| Eplerenone | 14 | $1,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $403 | $222,708156 claims |
| AstraZenecaFarxiga | $312 | $80,82576 claims |
| Novo NordiskOzempic, Wegovy | $469 | $80,76855 claims |
| Boehringer IngelheimJardiance | $303 | $48,57033 claims |
| Johnson & JohnsonXarelto | $73 | $37,02034 claims |
| Lilly USA, LLCMounjaro | $49 | $33,78130 claims |
| NovartisEntresto | $719 | $25,99415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Lone Tree
- Baran AksutLone Tree$32K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.